Gleixner, Amanda M.
Verdone, Brandie Morris http://orcid.org/0000-0001-7550-8536
Otte, Charlton G.
Anderson, Eric N.
Ramesh, Nandini
Shapiro, Olivia R.
Gale, Jenna R. http://orcid.org/0000-0003-2727-9497
Mauna, Jocelyn C.
Mann, Jacob R.
Copley, Katie E. http://orcid.org/0000-0003-0422-7475
Daley, Elizabeth L. http://orcid.org/0000-0003-2342-452X
Ortega, Juan A.
Cicardi, Maria Elena
Kiskinis, Evangelos http://orcid.org/0000-0001-8342-8616
Kofler, Julia
Pandey, Udai B. http://orcid.org/0000-0002-6267-0179
Trotti, Davide http://orcid.org/0000-0001-6338-6404
Donnelly, Christopher J. http://orcid.org/0000-0002-2383-9015
Funding for this research was provided by:
Amyotrophic Lateral Sclerosis Association (Milton Safenowitz Postdoctoral Fellowship)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke (NS086749, R01NS105756, R21NS098379)
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
U.S. Department of Health & Human Services | NIH | National Institute of Neurological Disorders and Stroke
Target ALS
Article History
Received: 10 January 2021
Accepted: 3 June 2022
First Online: 13 June 2022
Competing interests
: CJD is a scientific founder of Confluence Therapeutics. All other authors declare no competing interests.